Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer
- 1 June 2014
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 50 (9) , 1602-1609
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Taxanes: Still a Major Weapon in the Armamentarium Against Prostate CancerEuropean Urology, 2013
- Preclinical Antitumor Activity of Cabazitaxel, a Semisynthetic Taxane Active in Taxane-Resistant TumorsClinical Cancer Research, 2013
- Cabazitaxel in metastatic castration-resistant prostate cancerExpert Review of Anticancer Therapy, 2012
- Current and emerging treatment modalities for metastatic castration‐resistant prostate cancerBJU International, 2011
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialThe Lancet, 2010
- Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid TumorsClinical Cancer Research, 2009
- Prostate‐specific antigen flare phenomenon with docetaxel‐based chemotherapy in patients with androgen‐independent prostate cancerBJU International, 2008
- The postchemotherapy PSA surge syndromeAnnals of Oncology, 2008
- Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapyInternational Urology and Nephrology, 2007
- Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxelAnti-Cancer Drugs, 2006